10-Q: Biogen Q1 2026 Earnings: Revenue Up, EPS Soars

Biogen Inc. reported a 1.9% increase in total revenue to $2.48 billion and a 31.1% rise in diluted EPS to $2.15 for the first quarter of 2026.

Summary

• Biogen Inc. reported total revenue of $2.48 billion for the first quarter ended March 31, 2026, a 1.9% increase from $2.43 billion in the same period of 2025.
• Diluted earnings per share (EPS) increased by 31.1% to $2.15, up from $1.64 in the prior year's first quarter.
• Product revenue, net, increased by 1.5% to $1.75 billion.
• Revenue from anti-CD20 therapeutic programs increased by 10.8% to $419.1 million.
• Alzheimer's collaboration revenue, primarily from LEQEMBI, saw a significant 80.3% increase to $59.5 million.
• Contract manufacturing, royalty, and other revenue decreased by 15.8% to $246.9 million.
• Total costs and expenses decreased by 0.9% to $2.10 billion.
• Research and development (R&D) expenses increased by 24.2% to $539.0 million, largely due to higher amortization of SKYCLARYS inventory and increased clinical trial spending.
• Acquired in-process R&D, upfront, and milestone expenses decreased significantly by 83.1% to $34.0 million.
• Selling, general, and administrative (SG&A) expenses increased by 6.1% to $607.3 million, driven by increased sales and marketing activities for product launches.
• The company ended the quarter with $3.38 billion in cash and cash equivalents and $4.75 billion in total cash, cash equivalents, and marketable securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, with strong EPS growth and improved operational cash flow, despite ongoing challenges in the MS segment. The strategic acquisition of Apellis is a significant positive development.

Positives

• Total revenue increased by 1.9% to $2.48 billion.
• Diluted EPS saw a substantial increase of 31.1% to $2.15.
• Product revenue, net, grew by 1.5% to $1.75 billion.
• Strong growth in Alzheimer's collaboration revenue (LEQEMBI) by 80.3% to $59.5 million.
• Positive growth in revenue from anti-CD20 therapeutic programs by 10.8% to $419.1 million.
• Net cash flow from operating activities significantly increased by 148.9% to $645.5 million.
• Total costs and expenses decreased by 0.9%, indicating improved cost management.
• Cash, cash equivalents, and marketable securities increased to $4.75 billion, providing a strong liquidity position.
• The company announced a proposed acquisition of Apellis Pharmaceuticals for approximately $5.6 billion, which is expected to enhance its growth profile.
• Positive results from the Phase 2 part of the AMETHYST study for litifilimab in CLE were announced.

Negatives

• Global TECFIDERA revenue decreased by 46.9% to $109.5 million due to generic competition.
• Rest of world SPINRAZA revenue decreased by 14.0% due to unfavorable inventory dynamics and a one-time VAT refund in the prior year.
• Contract manufacturing, royalty, and other revenue decreased by 15.8% to $246.9 million.
• R&D expenses increased by 24.2% to $539.0 million, driven by higher amortization and clinical trial spending.
• SG&A expenses increased by 6.1% to $607.3 million, impacting profitability.
• The company anticipates total MS revenue will decline in 2026 due to increasing competition.
• The company expects TYSABRI sales to be adversely affected by biosimilar competition.
• The company expects global SPINRAZA revenue growth to be relatively flat in 2026.

Risks

• Increasing competition from new originator therapies, generics, prodrugs, and biosimilars for existing products.
• Potential limitations and pressures on product pricing due to governmental or regulatory requirements, including the IRA.
• Uncertainty regarding the successful commercialization of LEQEMBI and SKYCLARYS, including reimbursement and market acceptance.
• Dependence on the successful development of new products and additional indications for existing products, which is expensive and uncertain.
• Failure to effectively execute strategic and growth initiatives, including acquisitions.
• Inability to obtain and maintain adequate coverage, pricing, and reimbursement from payors.
• Risks associated with reliance on third-party collaborators and suppliers.
• Potential disruptions to information systems and data security breaches.
• Manufacturing issues, including reliance on third-party suppliers and compliance with cGMP regulations.
• Legal and regulatory risks, including patent litigation and government investigations.
• The impact of geopolitical tensions and global economic conditions on operations and supply chains.
• Potential adverse effects from healthcare reforms and drug pricing regulations.

Future Outlook

Biogen expects total MS revenue to decline in 2026 due to increasing competition. TECFIDERA revenue is expected to be further impacted by accelerating generic competition in the EU. TYSABRI sales are also expected to be adversely affected by biosimilar entrants. However, growth is anticipated from VUMERITY and continued launches of SKYCLARYS and QALSODY in rare diseases. R&D expenses are expected to increase in 2026 due to investments in late-stage programs and reduced funding from Royalty Pharma. SG&A expenses are expected to remain relatively flat compared to 2025.

Management Comments

• We believe that our existing funds, when combined with cash generated from operations and our access to additional financing resources, if needed, are sufficient to satisfy our operating, working capital, strategic alliance, milestone payment, capital expenditure and debt service requirements for the foreseeable future.
• We expect our core research and development expense to increase in 2026, primarily due to investments in our late-stage programs and the reduction of research and development funding received from Royalty Pharma.
• We anticipate higher net interest expense in 2026, compared to 2025, due to lower interest income driven by lower cash balances and higher interest expense resulting from additional financing related to our proposed acquisition of Apellis.
• We do not expect the tariffs currently applicable to our business to result in a material adverse effect on our operations in 2026.
• Although the long-term effects remain uncertain, this geopolitical conflict did not have any material effects on our results of operations for the three months ended March 31, 2026.

Industry Context

StockSavvy.ai notes that Biogen's Q1 2026 results reflect the ongoing challenges in the Multiple Sclerosis market due to generic competition, while also highlighting growth in newer areas like Alzheimer's disease with LEQEMBI. The proposed acquisition of Apellis Pharmaceuticals signals a strategic move to bolster the company's rare disease and immunology portfolio, aligning with broader industry trends of consolidation and focus on high-growth therapeutic areas.

Comparison to Industry Standards

• Biogen's R&D spending as a percentage of revenue (21.8%) is in line with or slightly higher than many large biopharmaceutical companies, reflecting a commitment to pipeline development.
• The significant increase in net cash from operations (148.9%) is a strong positive, outperforming many peers who may be facing margin pressures.
• The company's strategic acquisition of Apellis for $5.6 billion is a substantial move, comparable to other major M&A activities seen in the biopharma sector aimed at acquiring commercial-stage assets and expanding market reach.
• The revenue growth in Alzheimer's collaboration (LEQEMBI) is notable, as this is a rapidly evolving and competitive therapeutic area where early market penetration is key.

Legal Proceedings

• Securities litigation is ongoing, with one action dismissed and appealed, and another nearing settlement.
• Derivative actions related to ADUHELM and LEQEMBI are stayed.
• IMRALDI patent litigation is ongoing in Germany and France, with Biogen challenging patent validity.
• Humana filed suit against Biogen related to patient assistance programs.
• Genentech litigation regarding TYSABRI royalties resulted in a judgment against Biogen, which is under appeal.
• Antitrust litigation has been filed by various parties alleging violations of antitrust laws related to TECFIDERA and VUMERITY contracts.
• Neurimmune litigation concerns rights under a terminated collaboration agreement for aducanumab.
• TECFIDERA EU litigation is ongoing with generic companies, and a European Commission decision on regulatory protection was annulled and is under appeal.
• A German tax authority issued assessments against Biogen, which are being challenged.
• The Italian Competition Authority is investigating Biogen regarding its biosimilar product BYOOVIZ.
• The Louisiana Department of Justice requested information regarding Biogen's policies on purchases by healthcare organizations under Section 340B of the PHS Act.
• The European Commission Directorate-General for Competition requested information regarding TECFIDERA.
• TYSABRI biosimilar patent litigation is ongoing against Sandoz Inc.

Stakeholder Impact

• Shareholders are likely to benefit from the strong EPS growth and the strategic acquisition of Apellis, which aims to enhance long-term revenue.
• Patients may see continued access to innovative therapies for MS, Alzheimer's, and rare diseases, with potential for new treatments like litifilimab.
• The company's reliance on collaborations (e.g., with Eisai for LEQEMBI, Genentech for anti-CD20 therapies) means that the performance and decisions of these partners can impact Biogen.
• Creditors may be impacted by the planned increase in bank loans to finance the Apellis acquisition.

Next Steps

• Complete the proposed acquisition of Apellis Pharmaceuticals.
• Continue to advance the development and commercialization of LEQEMBI and SKYCLARYS.
• Monitor and manage the impact of generic and biosimilar competition on MS products.
• Continue to invest in pipeline development, particularly in late-stage programs.
• Manage R&D and SG&A expenses effectively.

Key Dates

Recommendation

While Biogen demonstrated strong EPS growth and improved operational cash flow in Q1 2026, the ongoing challenges in its core MS business due to generic competition and the significant investment required for the Apellis acquisition warrant a cautious approach. The company's future growth is heavily reliant on the successful integration of Apellis and the continued uptake of its newer products like LEQEMBI. The significant R&D spend and ongoing legal challenges also present risks. Therefore, a 'hold' recommendation is appropriate pending further clarity on these factors.

Keywords

Biogen, 10-Q, Quarterly Report, Financial Results, Revenue, Earnings Per Share, MS, Multiple Sclerosis, Alzheimer's, LEQEMBI, SPINRAZA, SKYCLARYS, QALSODY, TYSABRI, TECFIDERA, VUMERITY, Biosimilars, Apellis Acquisition